It would be interesting to explore combining clinically approved agents, such as trametinib (a MEK inhibitor) and bevacizumab (an anti-VEGF monoclonal antibody), for potential repurposing in PM-associated lung cancer treatment. The gene discussed is MAP2K7; the disease is lung carcinoma.